Journal Mobile Options
Table of Contents
Vol. 27, No. 3, 1989
Issue release date: 1989
Gynecol Obstet Invest 1989;27:137–142
(DOI:10.1159/000293641)
Original Paper

Measurement of CEA, TPA, Neopterin, CA125, CA153 and CA199 in Sera of Pregnant Women, Umbilical Cord Blood and Amniotic Fluid

Lellé R.J.a · Henkel E.b · Leinemann D.a · Goeschen K.a
aDepartment of Obstetrics and Gynecology (Director: Prof. J. Schneider) and bDepartment of Clinical Chemistry (Director: Prof. A. Delbrück), Medical School Hannover, FRG

Abstract

The following tumor markers were determined in body fluids associated with pregnancy: carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), neopterin, CA125, CA153 and CA199. CEA levels (cut-off 5.0 ng/ml) were not elevated during gestation, whereas TPA was above cut-off (85 U/l) in 98 out of 107 cases (range 40–408 U/l). TPA was significantly higher during the 3rd trimester of pregnancy than during the 1st and 2nd trimesters. 38.3% of CA125 measurements were slightly above the chosen cut-off of 35 U/ml, and the mean concentration was 33.5 ± 16.2 U/ml. During delivery, 14 out of 21 values (67%) were elevated. Only 9.4% of CA153 values were elevated. CA199 and neopterin were also hardly ever above cut-off. In general, there was a wide scattering of individual values. With the exception of CA153 (neopterin not determined), high concentrations of CEA (maximum: 207 ng/ml), TPA (maximum: 1,565 U/ml), CA125 (maximum: 2,371 U/ml) and also CA199 (maximum: 1,533 U/ml) were found in amniotic fluid. The distribution in mixed cord blood was similar but with more moderate elevations and a lower incidence of levels above cut-off. Thus, none of these antigens is tumor specific. The term ‘tumor-associated antigen’ instead of ‘tumor marker’ is more appropriate. CEA, TPA, CA125 and CA199, but not CA153, are oncofetal antigens. Thus, if a pregnant woman has cancer or is followed up after malignant disease, the use of CEA, CA199 and CA153 can be recommended. TPA will yield a high percentage of false-positive values, whereas a higher cut-off for the CA125 assay in pregnancy (e.g. 90 U/ml) is recommended.

 goto top of outline Author Contacts

Privatdozent Dr. med. Ralph J. Lellé, Medical School Hannover, Department of Obstetrics and Gynecology, Podbielskistrasse 380, D-3000 Hannover 51 (FRG)


 goto top of outline Article Information

Received: January 18, 1988
Accepted: April 7, 1988
Published online: March 02, 2010
Number of Print Pages : 6


 goto top of outline Publication Details

Gynecologic and Obstetric Investigation

Vol. 27, No. 3, Year 1989 (Cover Date: 1989)

Journal Editor: D'Hooghe T. (Leuven)
ISSN: 0378-7346 (Print), eISSN: 1423-002X (Online)

For additional information: http://www.karger.com/GOI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.